The Impact of Sex Hormone-Binding Globulin Levels on Thromboembolic Events at Patients with Advanced Stage Adenocarcinoma
No Thumbnail Available
Date
2022-01-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
KARE PUBL
Abstract
OBJECTIVE Several studies have shown that increased risk of venous thromboembolism (VTE) with hormonal contraceptives is mediated through the sex hormone-binding globulin (SHBG) through different pathways. Assuming SHBG as surrogate marker for hormonal stimulus as an increasing risk factor for VTE, we investigated if background SHBG has any impact on VTE in patient with advanced stage adenocarcinoma. Blood drawn from patients with VTE (n=45) and from patients without VTE (non-VTE
n=23), as a control group without a history of VTE, and SHBG levels were compared between goups. There was no difference in SHBG levels between VTE (59.7 +/- 41.5) and non-VTE (60 +/- 49) (p=0.71) group, but gastric cancer patients had statistically higher SHBG levels (73.7 +/- 39.9
range from 36.6 to 176.2) than rest of the cohort (56.54 +/- 44.4
range from 9.6 to 246.6) (p=0.033), although it was out of scope of this study. Although our study did not show any impact of SHBG levels on risk of VTE at patients with advanced stage adenocarcinoma, it revealed high levels of SHBG at gastric cancer patients which deserve further research. METHODS Blood drawn from patients with VTE (n=45) and from patients without VTE (non VTE
n=23), as a control group without a history of VTE, and SHBG levels were compared between groups. RESULTS There was no difference in SHBG levels between VTE (59.7 +/- 41.5) and non-VTE (60 +/- 49) (p=0.71) group, but gastric cancer patients had statistically higher SHBG levels (73.7 +/- 39.9
range from 36.6 to 176.2) than rest of the cohort (56.54 +/- 44.4
range from 9.6 to 246.6) (p=0.033), although it was out of scope of this study. CONCLUSION Although our study did not show any impact of SHBG levels on risk of VTE at patients with advanced stage adenocarcinoma, it revealed high levels of SHBG at gastric cancer patients which deserve further research.
n=23), as a control group without a history of VTE, and SHBG levels were compared between goups. There was no difference in SHBG levels between VTE (59.7 +/- 41.5) and non-VTE (60 +/- 49) (p=0.71) group, but gastric cancer patients had statistically higher SHBG levels (73.7 +/- 39.9
range from 36.6 to 176.2) than rest of the cohort (56.54 +/- 44.4
range from 9.6 to 246.6) (p=0.033), although it was out of scope of this study. Although our study did not show any impact of SHBG levels on risk of VTE at patients with advanced stage adenocarcinoma, it revealed high levels of SHBG at gastric cancer patients which deserve further research. METHODS Blood drawn from patients with VTE (n=45) and from patients without VTE (non VTE
n=23), as a control group without a history of VTE, and SHBG levels were compared between groups. RESULTS There was no difference in SHBG levels between VTE (59.7 +/- 41.5) and non-VTE (60 +/- 49) (p=0.71) group, but gastric cancer patients had statistically higher SHBG levels (73.7 +/- 39.9
range from 36.6 to 176.2) than rest of the cohort (56.54 +/- 44.4
range from 9.6 to 246.6) (p=0.033), although it was out of scope of this study. CONCLUSION Although our study did not show any impact of SHBG levels on risk of VTE at patients with advanced stage adenocarcinoma, it revealed high levels of SHBG at gastric cancer patients which deserve further research.
Description
Keywords
Adenocarcinoma, sex hormone-binding globulin, venous thromboembolism